Clinical and economic evaluation of PCSK9 inhibitor therapy

Despite growing evidence supporting PCSK9 therapeutic strategies for patients who cannot achieve guideline-established levels of LDL-C reduction even with high-intensity statin therapy, or for patients with a reduced capacity to tolerate appropriate doses of other lipid- lowering medications, there remain several outstanding questions on the clinical, comparative and cost effectiveness of PCSK9 inhibitors. This project will focus on longer run treatment effects for specific high risk patients, assessment of biomarkers and candidate mechanisms that could improve treatment targeting and more robust modelling of the comparative and cost effectiveness of these therapies. The methods will encompass both experimental and observational study designs, the use of evidence synthesis techniques, analysis of clinical variables and biomarkers and the application of modern approaches to the economic modelling of cost-effectiveness and programme evaluation.

Start date: September 2018